New drug reduces heart attacks, but is that enough?


A big, lengthy-time period research of a brand new Merck ldl cholesterol drug exhibits that it prevents coronary heart assaults and reduces the necessity for coronary heart procedures.

However the drug, anacetrapib, solely lowered these problems by 9 %, leaving Merck in a quandary. After spending thirteen years and certain lots of of tens of millions of dollars testing the drug, the corporate has to determine whether or not to spend much more to hunt approval from regulators and persuade individuals to purchase it in a market filled with ldl cholesterol medicine.

The outcomes of the 30,450-affected person research have been introduced Tuesday at a convention of coronary heart specialists in Barcelona, Spain and revealed within the New England Journal of Drugs.



Source link